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Endothelial cells (ECs) are dynamic cells that turn from growth into senescence, the latter being associated with cellular
dysfunction, altered metabolism, and age-related cardiovascular diseases. Aldehyde dehydrogenase 2 (ALDH2) is a
mitochondrial enzyme metabolizing acetaldehyde and other toxic aldehydes, such as 4-hydroxynonenal (4-HNE). In conditions
in which lipid peroxidation products and reactive oxygen species (ROS) are accumulated, ECs become dysfunctional and
significantly contribute to the progression of vascular-dependent diseases. The aim of the present study has been to investigate
whether inhibition of ALDH2 alters endothelial functions together with the impairment of bioenergetic functions, accelerating
the acquisition of a senescent phenotype. HUVECs transfected with siRNA targeting ALDH2 or treated with daidzin, an
ALDH2 inhibitor, were used in this study. We observed an alteration in cell morphology associated with endothelial
dysfunctions. Loss of ALDH2 reduced cell proliferation and migration and increased paracellular permeability. To assess
bioenergetic function in intact ECs, extracellular flux analysis was carried out to establish oxygen consumption rates (OCR). We
observed a decrease in mitochondrial respiration and reserve capacity that coincided with SA-β-Gal accumulation and an
increase in p21 and p53 expression in siALDH2 or daidzin-treated HUVECs. Treatment with N-acetyl-L-cysteine (NAC)
reduced endothelial dysfunctions mediated by siALDH2, indicating that oxidative stress downstream to siALDH2 plays an
instrumental role. Our results highlight that ALDH2 impairment accelerates the acquisition of a premature senescent
phenotype, a change likely to be associated with the observed reduction of mitochondrial respiration and reserve capacity.
1. Introduction
The aging process reflects the age-dependent functional
decline of body tissues and organs [1]. The progressive
decline also affects the vascular endothelium, resulting in an
impairment of its important functions such as the capacity
to supply nutrients and growth factors to organs, the barrier
function, and the capacity to form new vessels or angiogene-
sis [2, 3]. Vascular cell senescence is widely considered one of
the causative factors of peripheral and central nervous system
pathologies [4], as it promotes reactive oxygen species (ROS)
production and the ensuing vascular inflammatory responses
[5]. For instance, frequent stroke episodes in patients affected
by cerebral amyloid angiopathy (CAA) are related to the
perivascular deposition of amyloid beta peptides (Aβ), which
promote ROS production and, in turn, reduce endothelial
cell (EC) responsiveness. Similarly, in MELAS, a disease
characterized by encephalomyopathy, high ROS levels,
derived from dysfunctional mitochondria, compromise EC-
mediated vasodilatation, which explains the susceptibility of
these patients to stroke-like episodes [6–8]. Besides increased
ROS production, nine hallmarks have been proposed to con-
tribute to the aging phenotype, including the phenomenon of
cellular senescence as a stable arrest of cell cycle coupled with
phenotypic changes, mitochondrial dysfunction, and activa-
tion of the p53 pathway [1].
Even though ECs appear to meet most of their energy
needs anaerobically, they have an extensive mitochondrial
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network and consume oxygen. Their mitochondria are essen-
tial to endothelial functions [9–11]. It is broadly accepted
that, as cells are exposed to stressors, mitochondria are able
to rely on a “reserve capacity,” referred to as the difference
between the maximum respiratory capacity and the basal
respiratory capacity. This reserve capacity is suitable to pro-
vide the increased energy demands to preserve cellular func-
tions and repair or detoxification of reactive species [11, 12].
In this study, we sought to gain insights into the role of
endothelial mitochondria in the senescence process, taking
advantage of the recent progress gathered on the role of alde-
hyde dehydrogenases (ALDHs), particularly ALDH2 iso-
zyme (one of 19 enzymes belonging to the same
superfamily). The ALDH2 isozyme is located in the mito-
chondrial matrix and is predominantly responsible for the
acetaldehyde detoxification in alcohol metabolism. It is also
a key to detoxification of endogenous aldehydes, such as 4-
hydroxy-2-nonenal (4-HNE), which arise from lipid peroxi-
dation under oxidative stress, and of exogenous aldehyde
products, such as acrolein from tobacco smoke and car
exhausts [13, 14]. Increasing evidence has revealed a cardio-
protective and neuroprotective role of ALDH2 in myocardial
ischemia-reperfusion injury and Aβ-induced damage,
respectively. Studies from our laboratory have provided evi-
dence on the contribution of ALDH2 to Aβ-induced endo-
thelial dysfunction and on the possibility of preserving the
endothelial function in some pathological conditions by acti-
vating the ALDH2 enzyme [15]. In this study, we focused on
ALDH2 and its role as a critical metabolic checkpoint for
endothelial function. The aim of the study was to move
beyond correlative analyses between ALDH2 and hallmarks
of aging, providing causal evidence of the implication of
ALDH2 in endothelial senescence.
2. Materials and Methods
2.1. Cell Cultures. Human umbilical vein endothelial cells
(HUVECs) (Lonza, Basel, Switzerland) were used. Cells were
cultured on gelatin-coated dishes with endothelial growth
medium (EGM-2) (Lonza) supplemented with antibiotics
(100U/ml penicillin and 100μg/ml streptomycin, Euroclone,
Milan, Italy), glutamine (2mM, Euroclone), and 10% fetal
bovine serum (FBS, Hyclone, GE Healthcare, Little Chalfont,
UK). Progressively passaged HUVECs were utilized up to
senescence as already described [16]. The formula PD = ln
nch − ln ncs /ln 2was used to calculate the number of cumu-
lative population doublings (PD), where nch is the number of
cells harvested and ncs is the number of cells seeded.
2.2. Small Interfering RNA Transfection. Transient knock-
down experiments were performed using control and specific
siRNAs (OriGene, Rockville, MD, USA). Subconfluent cells
were seeded in 60mm or 100mm or 6-well plate dishes in
EGM-2 plus 10% FBS. After 24 h, cells were transfected in
endothelial basal medium (EBM-2) without serum and
antibiotics using Lipofectamine® 3000 (Invitrogen, Carlsbad,
CA, USA) and 20nM targeting siRNA (siALDH2) or scram-
bled control siRNA (siCTR) diluted in Opti-MEM (Gibco,
Thermo Fisher Scientific, Waltham, MA, USA). Serum was
added 6–8h posttransfection. Where indicated, cells were
harvested 24 h posttransfection. Cells were assayed 2–6 days
posttransfection. The transfection was repeated every 72 h.
We evaluated the knockdown efficiency using immunoblot-
ting or quantitative RT-PCR (qRT-PCR) analysis at the
indicated time.
2.3. Immunoblot Analysis. Subconfluent cells were plated in
60mm or 100mm or 6-well plate gelatin-coated dishes and
transfected as above or treated with 10μM daidzin, for 48 h.
Daidzin was dissolved in DMSO (Sigma-Aldrich). The treat-
ment with daidzin was repeated every day. Where indicated,
siCTR and siALDH2 HUVECs have been pretreated with
5mM N-acetyl-L-cysteine (NAC), as reported [17]. Next,
cells were washed and lysed, and an equal amount of proteins
was used for immunoblot analysis, as described [15]. The
blotted membranes were incubated with anti-ALDH2 (Ori-
Gene), anti-p21, anti-Egr-1, anti-c-Myc (Cell Signaling Tech-
nology, Danvers, MA, USA), anti-tubulin, anti-p53 (Santa
Cruz, Heidelberg, Germany), anti-β-actin (Sigma-Aldrich),
anti-4-HNE (Abcam, Cambridge, United Kingdom), and
OXPHOS antibody cocktail kit (Abcam) antibodies. Super-
Signal West Pico Chemiluminescent Substrate (Thermo
Fisher Scientific) was used to develop signals, which were
detected and quantified by the ChemiDoc system and Quan-
tity One software (Bio-Rad, Hercules, CA, USA). For all
experiments using whole-cell lysate, β-actin or β-tubulin
was used as loading controls.
2.4. Real-Time PCR. The RNeasy Plus Kit (Qiagen, Hilden,
Germany) was used according to the manufacturer’s instruc-
tions to extract and prepare total RNA. A total amount of
1μg RNA was transcribed, and quantitative RT-PCR was
performed as reported [18]. The fold change expression was
determined using the comparative Ct method (ΔΔCt) nor-
malized to 60S ribosomal protein L19 expression. Data are
reported as fold change relative to siCTR (control), which
was set to 1.
2.5. ALDH Enzymatic Activity. The conversion of acetalde-
hyde to acetic acid was determined in order to evaluate
ALDH enzyme activity, as reported [15]. Briefly, 1× 106
of seeded cells were transfected as described above, and
after 48 h, cells were scraped into 100μl of CelLytic™
MT Cell Lysis (Sigma-Aldrich) supplied with protease
inhibitors (Sigma-Aldrich) and sodium orthovanadate
(Sigma-Aldrich). Then, lysates were centrifuged for 20min
at 4°C at 14000 × g. The protein content in the supernatant
was quantified in a Bradford assay. ALDH2 activity was mea-
sured in an assay mix (0.8ml) containing 100mM sodium
pyrophosphate (Sigma-Aldrich) at pH9 and 10mM NAD+
(Sigma-Aldrich) and 300μg of sample protein. Then, acetal-
dehyde (10mM, Sigma-Aldrich) was added to the cuvette to
start the reaction. NADH formation from NAD+ was moni-
tored at 25°C in a spectrophotometer Infinite F200 Pro at
340 nm (Tecan Life Sciences, Switzerland). Where indicated,
supernatants of HUVECs were challenged with daidzin for
10min before the acetaldehyde was added; the compound
was tested at 1 and 10μM to monitor the extent of ALDH
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inhibition in these cell lysates. Enzyme-specific activity was
expressed as % nmol NADH/minute/mg protein.
2.6. Cell Survival and Area. Cells were transfected with
siRNA for ALDH2 as described above. Then, cells were
harvested and seeded (1.5× 103/well) in triplicate in 96-
multiwell plates. Adherent cells were exposed to EBM-2 with
2% FBS for 2 and 5 days. Where indicated, HUVECs were
treated with 5mMNAC (Sigma-Aldrich) before the adminis-
tration of 2% FBS. This treatment was repeated every three
days. Further, HUVECs were also pretreated for 30min with
10μM daidzin in EBM-2 before the administration of 2%
FBS for 2 or 5 days. Then, cells were fixed and stained with
the PanReac kit (Darmstadt, Germany), and five fields per
well were counted. Data are analyzed in triplicate, and results
are expressed as the cell number counted/well. To calculate
the area of cells, three fields in which cells were at 60% con-
fluence for each condition were measured using ImageJ soft-
ware and results are expressed as square pixel.
2.7. Senescence-Associated β-Galactosidase (SA-β-Gal)
Activity Assay. Cells were seeded in 6-well multiplates
(8× 104 or 1.5× 105 cells/well). Adherent cells were treated
with 10μM daidzin for 2 days or transfected with siRNA as
described above. Where indicated, 24 h posttransfection, a
preincubation of 30min with 5mM NAC was carried out
before the administration of 2% FBS. This treatment was
repeated every three days. At 2 and 6 days, SA-β-Gal activity
was assessed by using the Senescence β-Galactosidase Stain-
ing Kit (Cell Signaling) following the manufacturer’s manual.
Data are reported as a fold increase vs. siCTR of positive cells
for SA-β-Gal activity.
2.8. BrdU Incorporation Assay. Cell proliferative capacity
was evaluated using a chemiluminescence ELISA (Roche
Diagnostic S.p.A, Monza, Italy) which assesses the 5-
bromo-2′-deoxy-uridine (BrdU) incorporation. 3× 103 cells
were seeded in a 96-well plate in triplicate 24 h posttransfec-
tion. Adherent cells were exposed to EBM-2 in the presence
or absence of serum (2% and 0.1% FBS, respectively) for
48 h. 8 hours before the end of incubation, BrdU was added
in each well. Then, the assay was carried out as reported [18].
2.9. Wound Healing Assay. siRNA transfection of adherent
cells was conducted as described above, and after 24 h, cells
were harvested. siCTR, siALDH2, and wild-type HUVECs
were seeded (1× 105 cells/well) into 24-well plates and incu-
bated until they were grown into a confluent monolayer
(24–30 h). Then, a sterile 100–1000μl micropipette tip was
used to scrape the confluent monolayer and create a
wound± 500μm. The cells were washed twice with PBS and
exposed to fresh EBM-2 medium supplemented with 0.1 or
2% FBS and ARA-C (2.5mg/ml, Sigma-Aldrich) to suppress
cell proliferation. Where indicated, confluent HUVECs were
pretreated for 30min with daidzin and then treated with 2%
FBS. Images of the wound in each well were acquired from 0
to 18h under a phase contrast microscope at 10x magnifica-
tion. Then, cells were fixed and stained with the PanReac kit.
Results were quantified using ImageJ software, and data are
reported as % of scratch closure.
2.10. Immunofluorescence Microscopy Analysis. Cells were
transfected with siRNA as described above, and 24h post-
transfection, ECs were harvested and seeded (8× 104 cells)
on 8mm ø glass coverslips in triplicate. After 24 h, cells were
exposed to EBM-2 with 0.1% FBS for 8 h. 4% paraformalde-
hyde/PBS with Ca2+ and Mg2+and 3% bovine serum albumin
(BSA) were used to fix cells and block unspecific binding
sites, respectively. Then, cells were incubated with a mono-
clonal rabbit anti-VE-cadherin diluted to 1 : 400 (Cell Signal-
ing Technology) and a polyclonal rabbit anti-ZO-1 (Life
Technologies, Carlsbad, CA, USA) diluted to 1 : 50 in 0.5%
BSA in PBS for 18h at 4°C. After incubation with the second-
ary antibody, Alexa Fluor© 488-labeled anti-rabbit (1 : 200,
1 h, Invitrogen) and Alexa Fluor© 555-labeled anti-rabbit
(1 : 200, 1 h) were used for 1 h at room temperature, and then
the protocol was completed according to Terzuoli et al. [19].
Leica SP5 confocal microscopy (63x objective) was used to
capture images of stained cells.
2.11. Paracellular Permeability Assay. Cells were seeded
(8× 104 cells/well) 24 h post-ALDH2 silencing on gelatin-
coated insert membranes (0.4μm diameter pores, Corning,
New York, USA), and the inserts were placed in 24-
multiwell plates and incubated for 24h. Next, cells were
exposed to EBM-2 with 0.1% FBS for 8 h. The assay was
carried out as described [20]. Briefly, the fluorescent per-
meability tracer (3 kDa FITC-Dextran, 10μM) was added,
and the fluorescence was measured after 7min in the
medium present in the bottom of the well, in a multiplate
reader (Infinite 200 Pro, SpectraFluor, Tecan), at 485/
535 nm (excitation/emission). Results are reported as rela-
tive fluorescence units (RFU) [20].
2.12. ROS Measurement. siCTR and siALDH2 cells (24 h
posttransfection) were seeded (1.5× 103 cells/well) in tripli-
cate in a 96-well plate, and after adherence (6–8 h), the
medium was replaced with EBM-2 with 0.1% FBS in the pres-
ence or absence of 5mM NAC for 24 h. DCFH2-DA (2,-7-
dichlorodihydrofluorescein diacetate, Invitrogen) was used,
and intracellular ROS were measured as previously described
[20]. The results are reported as fold change vs. siCTR of rel-
ative fluorescence units (RFU) corrected for the cell number
counted [20].
2.13. Measurement of the Oxygen Consumption Rate. The
measurement of oxygen consumption rates (OCR) was car-
ried out using the Seahorse XF24 extracellular flux analyzer
as described previously [21, 22]. siCTR and siALDH2 ECs
were harvested and seeded 24h posttransfection in XF24 cell
culture plates at 3× 104 cells/well density in 200μl of EGM-2
supplemented with 10% FBS and incubated at 37°C in 5%
CO2 for 6–8h. Then, adherent cells were exposed to EBM-2
supplemented with 2% FBS for 24 h. Assays were performed
as reported [22]. Independent titration was routinely carried
out to determine the optimal concentration of FCCP (carbo-
nylcyanide-p-trifluoromethoxyphenyl hydrazone), which
was ranged between 0.2 and 0.4μM. Initially, a stable OCR
baseline was determined, and then, oligomycin, FCCP,
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rotenone, and antimycin A were supplied as reported in the
figure legend.
2.14. Transmission Electron Microscopy. 1× 104 cells trans-
fected with siRNA as above were harvested and seeded 24 h
posttransfection in a small chamber prepared with cylinder
part of BEEM® (Ted Pella Inc., Redding, CA, USA) capsule
glued to the coverslip as previously described [23]. After 6–
8h of incubation needed for adhesion, cells were exposed to
EBM-2 with 2% FBS for 24 h. The medium was replaced with
2.5% glutaraldehyde (Ted Pella, Redding, CA, USA) in 0.1M
phosphate buffer (pH7.2) for 2 h at RT and postfixed with
buffered 1% OsO4 (EMS, Hatfield, PA, USA) for 1 h and
processed by standard dehydration through a graded series
of ethanol (50°–100°). Specimens were then embedded in
pure Epon (EMS, Hatfield, PA, USA) resin. Polymerization
was done in an oven at 60°C for 48 h. Then, slides were
dropped into liquid nitrogen to detach the resin from cover-
slips. 60–70 nm thick sections were cut with an Ultracut E
(Reichert-Jung, Wien, AT) ultramicrotome, stained with ura-
nyl acetate and lead citrate, and examined in a TEM Jeol 1010
(Peabody, MA, USA) transmission electron microscope.
2.15. Statistical Analysis. Results are expressed as means± SD
or SEM. Statistical analysis was generated by GraphPad soft-
ware (San Diego, CA, USA). Statistical analysis was per-
formed by Student’s t-test and two-way ANOVA. p < 0 05
was considered statistically significant.
3. Results
3.1. ALDH2 Silencing or Inhibition Impairs Endothelial Cell
Functions. To examine the role of ALDH2 in endothelial
function, HUVECs were treated with 1 and 10μM daidzin,
an inhibitor of ALDH2 activity [14], or transiently
knocked down for ALDH2 (siALDH2) and compared with
wild-type cells transfected with an empty vector (siCTR),
throughout this work. 10μM daidzin was the higher con-
centration without a significant effect of its solvent on
HUVEC survival.
Whereas in siCTR cells ALDH2 protein expression was
easily detected by Western blot, the enzyme expression was
drastically reduced in siALDH2 (Figure 1(a)). Silencing of
ALDH2 also reduced the mRNA levels and activity of the
enzyme (Figures 1(b) and 1(c)) and promoted a significant
change in HUVEC morphology, characterized by the irregu-
lar elongated shape instead of the regular polygonal shape of
siCTR cells (Figure 1(d)). As expected, 10μM daidzin signif-
icantly reduced ALDH2 activity, while at 1μM, it did not
affect the enzyme activity (Figure 1(e)).
Next, we determined the involvement of ALDH2 activity
on cell viability, proliferation, and migration, as well as on
cell permeability, key features of endothelial cell functions.
The proliferation of siALDH2 ECs, assessed by the BrdU
incorporation assay, was significantly reduced relative to
siCTR ECs and not recovered in the presence of serum
(Figure 2(a)). Accordingly, both deficiency and pharmaco-
logical inhibition of ALDH2 in HUVECs resulted in a consis-
tent reduction of cell viability, particularly visible after 5 days
(Figures 2(b) and 2(c)). Moreover, cell migration, evaluated
by the scratch assay, was significantly inhibited in both
daidzin-treated and siALDH2 ECs (Figure 2(d)). ALDH2
ablation also affected the adherence and tight junctions
of HUVECs altering their barrier function. Indeed, in con-
fluent siCTR, the expression of VE-cadherin and ZO-1,
examined by immunofluorescence, was mainly localized
at cell-cell contacts and disappeared in cells whose ALDH2
was silenced (Figure 2(e)).
To corroborate the immunofluorescence analysis, we
evaluated the paracellular flux in a confluent monolayer of
siCTR and siALDH2 ECs. Consistent with the above data,
we observed an increase in permeability in siALDH2 when
compared to siCTR ECs, as shown by increased paracellular
flux of fluorescence-conjugated dextran (Figure 2(f)).
Of note, silencing the ALDH2 triggered the accumulation
of 4-HNE-induced covalent adducts, as well as ROS products
[24] in ECs (Figures 3(a) and 3(b)), suggesting that the intra-
cellular abundance of these toxic products might contribute
to the impairment of the endothelium and trigger the prema-
ture senescence process seen below.
To get insight into the role of ROS in the dysfunction of
ECs whose ALDH2 was silenced, 5mM NAC, a ROS scaven-
ger, was used. In particular, as shown in Figures 3(b)–3(e),
NAC treatment in siALDH2 ECs affected the pattern of
4-HNE protein adducts and reduced their expression, sig-
nificantly inhibited the production of total ROS levels, and
improved viability at 5 days. Taken together, these results
indicate that ALDH2 silencing affects the healthy phenotype
of HUVECs by increasing the accumulation of 4-HNE-
induced adducts and ROS products, leading to changes in
morphology and disassembling of intercellular junctions,
and impairs endothelial cell barrier function and mobiliza-
tion capacity.
3.2. ALDH2 Silencing or Inhibition Promotes the Onset of
Senescence in Endothelial Cells. In light of the above findings,
showing a pervasive dysfunction of endothelial cells upon
ALDH2 silencing, we wondered whether this impaired state
might be associated with the acquisition of premature senes-
cence. Morphological modifications characterize usually
senescent cells in in vitro culture: cells become large, flat, vac-
uolated, and occasionally multinucleated [25]. Therefore, we
quantified the size of the cells and reported it as the area of
the cells expressed as square pixel. siALDH2 cells presented
a larger cell area in comparison to siCTR cells (Figures 4(a)
and 4(b)). We next measured the cumulative population
doubling (PD) in long-term cultured endothelial cells at pre-
determined set points, an experimental protocol we devised
to study senescence [16]. We performed measurements of
PD and of several senescence markers at PD 5 and PD 21,
corresponding to the time-dependent progress from prema-
ture to moderate-full senescent cells, respectively. Senescent
cells vary from other nonproliferating cells by several
markers. Besides the expression of signals belonging to the
two major senescence-inducing pathways (p53/p21, c-Myc,
Egr-1), we also evaluated beta-galactosidase (SA-β-Gal) activ-
ity.As shown inFigures 4(c), 4(d), and4(g),HUVECs atPD21
overexpressed SA-β-Gal activity and senescence markers
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compared to HUVECs at PD 5. Of note, in HUVECs at PD 5
whose ALDH2 was silenced, we observed the overexpression
of p53 andp21, c-Myc, andEgr-1 (Figures 4(e), 4(f), and 4(h)).
In addition, evaluation of SA-β-Gal revealed significant
differences in its expression between siCTR PD 5 cells and
those of siALDH2 groups and PD 21 groups (see
Figure 4(i)). A time-related increase in SA-β-Gal expres-
sion (3- to 5-fold difference) was evident in siALDH2 but
not in siCTR cells (Figure 4(j)). Similarly, treatment with
10μM daidzin significantly increased senescence markers in
PD 5 ECs (Figures 4(k) and 4(l)). Of note, 5mM NAC
partially reversed SA-β-Gal expression in siALDH2 ECs
(Figure 4(m)), corroborating the instrumental role played
by ROS in the impairment of the endothelium whose
ALDH2 was silenced.
These data clearly indicate that ALDH2 silencing and
inhibition are associated with the onset of early signs of a
senescent phenotype.
3.3. ALDH2 Silencing Alters Bioenergetic Functions in
Endothelial Cells. Adjusting metabolism to a quiescent state
is central to normal vessel function [9, 10]. As we observed
that ablation of ALDH2 causes an impairment of perme-
ability leading to a senescent phenotype in HUVECs, we
investigated whether ALDH2 would affect cell oxidative
metabolism. We evaluated oxygen consumption rates
(OCR) in siCTR compared to siALDH2 at baseline and
in response to oligomycin (Oligo), fluoro-carbonyl cyanide
phenylhydrazone (FCCP), or antimycin A (AA) and rote-
none (R). We found that ALDH2 silencing reduced basal
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Figure 1: Characterization of siALDH2 and daidzin-treated HUVECs. (a) Immunoblotting and (b) qPCR analysis of ALDH2 silencing
(siALDH2) in ECs, 48 h posttransfection. Representative blots of at least 3 with similar results are shown. qPCR data are expressed as the
mean of fold change± SD vs. siCTR cells, which were assigned to 1. ∗∗p < 0 01 vs. siCTR. (c) ALDH2 activity measured in siALDH2 EC
lysates (48 h posttransfection). Data are presented as the mean± SD of % NADH production vs. siCTR. ∗p < 0 05 and ∗∗p < 0 01 vs.
siCTR. (d) Morphology of confluent monolayers of siCTR and siALDH2 B ECs fixed and stained 48 h posttransfection. A representative
image for each condition is shown. Scale bar: 100 μm. (e) ALDH2 activity measured in ECs in the presence or absence of daidzin (1–
10μM). D10: 10μM daidzin. Data are presented as the mean± SD of % NADH production vs. Ctr. ##p < 0 01 vs. Ctr.
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Figure 2: ALDH2 silencing or inhibition impairs endothelial functions. (a) BrdU incorporation in ECs transfected with siRNA for 24 h.
Proliferative capacity was assessed after 48 h treatment with 0.1%–2% FBS. Data are reported as mean± SD. ∗p < 0 05 vs. siCTR with 0.1%
FBS; #p < 0 05 and ##p < 0 01 vs. siCTR. (b) Cell survival in 10 μM daidzin-treated ECs or siCTR and siALDH2 ECs exposed to 2% FBS
for 2 and (c) 5 days. Data are expressed as means± SD of the cell number counted/well. Dimethyl sulfoxide (DMSO) is used as a solvent
to dissolve daidzin. No significant effect of DMSO was observed in HUVEC survival (DMSO-treated cell numbers/well: 329± 30). NS: not
statistically significant; #p < 0 05 vs. Ctr; ∗∗p < 0 01 vs. siCTR. D10: 10 μM daidzin. (d) Scratch assay in 10μM daidzin-treated ECs or in
siCTR and siALDH2 ECs cultured in 0.1% or 2% FBS for 18 h. Means± SD of % of scratch closure (##p < 0 01 vs. Ctr; ∗∗p < 0 01 vs.
siCTR). (e) Confocal analysis of VE-cadherin and ZO-1 patterns in control (i–iii) and siALDH2 ECs (ii–iv) after exposure to EBM-2 with
0.1% FBS for 8 h. Representative images of three experiments at 63x magnification are shown. Scale bar: 20μm. (f) Permeability in siCTR
and siALDH2 ECs detected as fluorescence-conjugated FITC-dextran diffusion through the confluent monolayers after exposure to EBM-
2 with 0.1% FBS for 8 h. ∗∗p < 0 01 vs. siCTR. Images are representative of results obtained with siALDH2 B.
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andmaximal respiration anddecreased the respiratory reserve
capacity (Figures 5(a) and 5(b)). Importantly, Western blot
analysis of constitutive respiratory complexes including CII,
CIII, and CIV, known to be sensible to the ROS increase in
mitochondria, indicated that ALDH2 did not alter the abun-
dance of these respiratory complexes (Figure 5(c)).
Given the significant changes of the metabolic function
reported, we assessed whether they were associated with
morphological modification of cellular components. TEM
images showed minor morphological changes in mitochon-
dria of siALDH2 cells (Figure 6). In particular, smaller mito-
chondria in Figure 6(b) were observed when compared to
those in Figure 6(a), and cristae in the centre of mitochondria
in Figure 6(d) appear to be deleted.
In conclusion, bioenergetic analysis revealed that ALDH2
deficiency specifically reduced bothmitochondrial respiration
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Figure 3: ALDH2 silencing increases 4-HNE protein adducts and ROS levels. (a) Western blot analysis of 4-HNE protein adducts in siCTR
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arrows indicate bands quantified in (d). Representative blots of at least 3 with similar results are shown. (b) ROS production in
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counted/well. ∗p < 0 05 vs. siCTR. Images are representative of results obtained with siALDH2 B.
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8 Oxidative Medicine and Cellular Longevity
and reserve capacity, which presumably contribute to the
reduction of the endothelial responsiveness.
4. Discussion
ALDH2, a mitochondrial enzyme, is known for its detoxify-
ing properties, which provide living organisms with a protec-
tive shield against endogenous and exogenous toxic agents
[26], such as acetaldehyde (alcohol metabolism) and prod-
ucts originating from lipid peroxidation (4-HNE) and ROS.
The relevance of ALDH2 in providing strong protection
toward toxic insults has been described in numerous reports,
demonstrating its efficacy in various models of human dis-
eases such as ischemia-reperfusion and ischemic stroke char-
acterized by overwhelming oxidative stress [27]. Note that
the above pathologies have the vascular endothelium as an
underlying component whose function might be compro-
mised by ROS and aldehyde surge.
Previous data from our group documented that alteration
in endothelial function induced by Aβ was restored by the
activation of mitochondrial ALDH2 in the endothelium
[15]. However, the contribution of ALDH2 to endothelial
senescence remains unresolved.
Here, we have described the role of ALDH2 in endothe-
lial growth and function, using HUVECs as a model, whose
ALDH2 was silenced through transfection of targeting
siRNA or exposure to the pharmacological inhibitor of
ALDH2, daidzin. The resulted cellular models displayed a
number of morphological and functional changes. Morpho-
logically, we observed a subverted phenotype of silenced cells,
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∗∗∗p < 0 001, ∗∗p < 0 01, and ∗p < 0 05 vs. siCTR. (i) Images of SA-β-Gal staining of siCTR and siALDH2 ECs and PD 21 groups obtained
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representative of results obtained with siALDH2 B.
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characterized by an enlarged and elongated cell shape, in
sharp contrast to the polygonal one of wild-type endothelial
cells. Functionally, the ALDH2 loss yielded a reduced mobil-
ity and augmented permeability, a finding consistent with the
marked decline of VE-cadherin and ZO-1 expression at cell-
cell contacts and with the changes in cell morphology. We
also observed a reduction of cell proliferation that results
in a reduction of the cell number. Predictably, ALDH2
silencing produced intracellular accumulation of 4-HNE
adducts and ROS production, which appears to be the pri-
mary cause of the observed impairment of endothelial cell
functions and morphological changes, as corroborated by
using the scavenger NAC.
The study of mitochondrial respiration provided fur-
ther insight into the mechanism underlying endothelial
dysfunction, as mitochondria possess a considerable respi-
ratory reserve, which is important in the response to
oxidative stress [11, 12]. Indeed, we found that ALDH2
silencing diminished the inherent oxidative metabolism,
as indicated by a decline in the oxygen consumption rate.
Specifically, siALDH2 cells showed a reduction in basal
and maximal respiration measured under basal conditions
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Figure 5: ALDH2 silencing is associated with mitochondrial dysfunction. (a) OCR was assessed by a Seahorse XF24 cell culture microplate in
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and in response to FCCP, with a clear decrease in the
reserve capacity. While mitochondrial respiration decreased,
the analysis of the expression of all respiratory complexes
does not change upon ALDH2 downregulation, indicating
that the protein level of all respiratory complexes is not the
leading cause of reduced respiration in siALDH2 cells. We
therefore suggested that the decrease in basal OCR and spare
reserve capacity might be due to some posttranslational
modifications.
Furthermore, TEM images suggest alterations in mito-
chondrial morphology of siALDH2 cells. Thus, the endo-
thelial dysfunction, noted in siALDH2 cells and in ECs
exposed to daidzin, may be attributed to the effects of accu-
mulated toxic products and to subtle defects of mitochon-
drial respiration.
Investigation on endothelial cell senescence was initiated
in view of the observed morphological similarities between
siALDH2 and those typical of senescent cells, i.e., the flat
morphology and enlarged cell size. Evidence sustaining the
hypothesis of an incipient senescent state was gleaned from
the analysis of SA-β-Gal activity and specific intracellular
signals measured in siALDH2 cells and in daidzin-treated
cells subjected to stress-induced senescence experiments in
which population doublings (PD) were recorded. Indeed,
cellular senescence ensued as early as at PD 5 progressing
steadily up to PD 21. In fact, increases in signals, e.g.,
SA-β-Gal, p21/p53, Egr1, and c-Myc, were noted when com-
paring signalling patterns at PD 5 vs. PD 21. The onset of
senescence in siALDH2 cells as well as in ECs exposed to
daidzin is considerably faster than what was observed in the
earlier work on HUVECs exposed to exogenous amyloid
peptides (PD 5 vs. PD 21) [16]. This underscores the
protective role of ALDH2 exerted toward the endothelium
to an extent not appreciated before.
5. Conclusions
Our results demonstrate that in the vascular endothelium,
loss of ALDH2 accelerates the acquisition of a premature
senescence phenotype leading to endothelial dysfunction.
These events are associated with an increase in ROS
levels, accumulation of 4-HNE protein adducts, and
impairment of mitochondrial bioenergetic functions. The
senescence phenotype of the endothelium, with exhaustion
of the regenerative capacity, may represent a defensive
response from the damage caused by an accumulation of
toxic aldehydes and can lead to the expansion of the
senescent cell population further aggravating the loss of
function in the vasculature.
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